0.00Open0.12Pre Close0 Volume51 Open Interest10.50Strike Price0.00Turnover553.77%IV58.86%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.1229Delta0.0898Gamma55.71Leverage Ratio-0.1176Theta0.0000Rho6.85Eff Leverage0.0008Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet